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Abstract
Background: The development of bronchial hyperreactivity (BHR) subsequent to precapillary pulmonary
hypertension (PHT) was prevented by acting on the major signalling pathways (endothelin, nitric oxide, vasoactive
intestine peptide (VIP) and prostacyclin) involved in the control of the pulmonary vascular and bronchial tones.
Methods: Five groups of rats underwent surgery to prepare an aorta-caval shunt (ACS) to induce sustained
precapillary PHT for 4 weeks. During this period, no treatment was applied in one group (ACS controls), while the
other groups were pretreated with VIP, iloprost, tezosentan via an intraperitoneally implemented osmotic pump, or
by orally administered sildenafil. An additional group underwent sham surgery. Four weeks later, the lung
responsiveness to increasing doses of an intravenous infusion of methacholine (2, 4, 8 12 and 24 μg/kg/min) was
determined by using the forced oscillation technique to assess the airway resistance (Raw).
Results: BHR developed in the untreated rats, as reflected by a significant decrease in ED50, the equivalent dose of
methacholine required to cause a 50% increase in Raw. All drugs tested prevented the development of BHR,
iloprost being the most effective in reducing both the systolic pulmonary arterial pressure (Ppa; 28%, p = 0.035)
and BHR (ED50 = 9.9 ± 1.7 vs. 43 ± 11 μg/kg in ACS control and iloprost-treated rats, respectively, p = 0.008).
Significant correlations were found between the levels of Ppa and ED50 (R = -0.59, p = 0.016), indicating that
mechanical interdependence is primarily responsible for the development of BHR.
Conclusions: The efficiency of such treatment demonstrates that re-establishment of the balance of constrictor/
dilator mediators via various signalling pathways involved in PHT is of potential benefit for the avoidance of the
development of BHR.
Background
There has recently been substantial progress in the devel-
opment of new therapeutic strategies for the manage-
ment of patients with pulmonary hypertension (PHT)
[1-5]. The improvements are based on a better under-
standing of the mechanisms involved in the development
of PHT. These treatment strategies are based on the
recognition that a key role is played in the modulation of
the tone of the smooth muscle cells in the pulmonary
vasculature by an imbalance between the vasoactive con-
strictor and proliferative mediators (endothelin-1 (ET-1),
substance P and angiotensin II) and the vasorelaxing and
antiproliferative mediators (adrenomedullin, vasoactive
intestinal peptide (VIP), prostacyclins (PCs) and nitric
oxide (NO)) [6]. The bronchoactive potential of these
peptides has been recognized as the major cause of the
lung function deterioration [1,2,7-10].
We earlier reported a lung function impairment in a
reproducible model of precapillary PHT following the
creation of a shunt between the abdominal aorta and the
vena cava in rats [11]. We also demonstrated that preca-
pillary PHT leads to the development of bronchial hyper-
responsiveness (BHR) to methacholine subsequent to the
altered mechanical interdependence between the pulmon-
ary vasculature and the respiratory tract. Although novel
strategies are available for the treatment of pulmonary
vascular diseases, no studies have yet characterized how
the adverse pulmonary consequences of these clinically
important pulmonary vascular abnormalities can be pre-
vented. Accordingly, in the present study we set out to
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prevent the adverse changes in the lung function and
bronchial responsiveness by acting on the imbalance
between the vasoactive constrictor-proliferative and
vasorelaxing-antiproliferative mediators.
Methods
Animal preparations
The experimental protocol was approved by the
Experimental Ethics Committee of the University of
Geneva and the Animal Welfare Committee of the
Canton of Geneva. Fifty-six adult male Sprague-Dawley
rats (weighing 312-382 g) were anaesthetized by an
intraperitoneal injection of pentobarbital (70-90 mg/kg
of a 50 mg/ml solution). Tracheal intubation was
achieved with a polyethylene cannula (16-gauge, Braun,
Melsungen, Germany) and the rats were mechanically
ventilated with a tidal volume of 7 ml/kg body weight,
a positive end-expiratory pressure of 2.5 cm H2O, and
a respiratory rate of 70-80/min (model 683, Harvard
Apparatus Co Inc., South Natick, MA, USA). Anesthe-
sia was maintained with pentobarbital administered
intravenously every 40 min (5 mg/kg). The femoral
vein was cannulated for drug delivery. The airway
pressure, ECG and rectal temperature were monitored
continuously by a data collection and acquisition sys-
tem (Biopac, Santa Barbara, CA, USA). Fentanyl was
administered intravenously (15 μg/kg) to ensure ade-
quate analgesia before the administration of pancuro-
nium intravenously (0.4 mg/kg) to facilitate forced
oscillatory measurements. To ensure adequate post-
operative analgesia, buprenorphine (0.5 mg/kg) was
injected subcutaneously before emergence from
anesthesia and again 18 h after surgery.
Induction of precapillary pulmonary hypertension
The surgical induction of precapillary PHT was per-
formed as described in detail previously [11-13]. Briefly, a
midline abdominal incision was made in a sterile manner
and the infra-renal portions of the abdominal aorta and
inferior vena cava were exposed at the site where the two
vessels share a common fascia. An aorto-caval shunt
(ACS) was then prepared by introducing a needle
between the two vessels, followed by application of an
aortic adventitial suture. In the rats that received various
treatments (see below), an osmotic intraperitoneal pump
(Alzet model 2ML4, Alza corporation, Palo Alto, USA)
was implanted intraperitoneally into the lower abdomen
in order to allow continuous delivery of the different
drug medications during 4 weeks. The abdomen was
closed in a sterile manner and a long-acting local anes-
thetic (bupivacaïne 0.25%, 0.8-1.2 ml) was infiltrated
around the surgical wounds.
Treatments, protocol groups
After creation of the ACS, the animals were randomized
to be included in one or other of the groups detailed
below (Figure 1). The route of administration of the
treatment agents and the doses were chosen on the
basis of their pharmacokinetic properties and the manu-
facturers’ recommendations.
Group CC (n = 13)
These control rats underwent the surgical procedure as
detailed above, but without preparation of the ACS.
A subgroup (n = 7) of these animals underwent sham sur-
gery and implementation of an intraperitoneal pump for
the continuous delivery of normal saline in the 4-week
period, while the remaining rats were not implanted with
the pump (n = 6). Since there was no difference between
these sham subgroups in the data relating to any of the
parameters measuring hemodynamics or respiratory
mechanics, their data were pooled for further analyses.
Group CS (n = 10)
An ACS was prepared in these animals, but no subse-
quent drug treatment was applied.
Group VIP (n = 8)
To test the VIP pathway in affecting PHT and the subse-
quent BHR, rats with an ACS received VIP 150 μg/kg/day,
administered via the intraperitoneal pump (2.5 μl/h) for
4w e e k s .
Group ILO (n = 10)
To study the PC pathway in influencing PHT and the
subsequent BHR, rats with ACS received iloprost 80 μg/
kg for 4 weeks via the intraperitoneal pump (5 μl/h).
Group SIL (n = 7)
To investigate the role of NO in the precapillary PHT
and the subsequent BHR, ACS preparation was followed
by a 4-week treatment with sildenafil administered orally
(25 mg/day dissolved in 1.5 ml saline).
Group TEZ (n = 8)
To explore how the ET-1-related mechanisms affect the
precapillary PHT and the subsequent BHR, rats with an
ACS were treated for 4 weeks with the combined ETA-ETB
receptor blocker tezosentan (10 mg/kg/day) administered
via an intraperitoneal pump (2.5 μl/h).
Measurements of end-expiratory lung volume (EELV)
EELV measurements were accomplished in all groups with
a body plethysmograph, as detailed previously [14]. Briefly,
the trachea was occluded at end expiration until 3 or 4
spontaneous inspiratory efforts had been generated by the
animal in the closed box. The changes in tracheal pressure
and plethysmograph box pressure during these man-
oeuvres were recorded, and EELV was calculated by apply-
ing Boyle’s law to the relationship between the tracheal
pressure and the box pressure after correcting for the box
impedance [15].
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T h ec o n t r i b u t i o n so ft h ea i r w a ya n dt i s s u em e c h a n i c a l
properties to the total respiratory resistance were esti-
mated by the forced oscillation technique by measuring
the mechanical impedance of the respiratory system
(Zrs), as described in detail previously [16,17]. Briefly, the
tracheal cannula was connected from the respirator to a
loudspeaker-in-box system at end-expiration. Zrs was
measured with the wave-tube technique by introducing
pseudorandom forced oscillations at frequencies between
0.5 and 21 Hz at end-expiration. Two identical pressure
transducers (Model 33NA002D, ICSensors, Malpitas, CA,
USA) were used to measure the lateral pressures at the
loudspeaker and at the tracheal end of the wave-tube,
and Zrs was calculated as the load impedance of the
wave-tube by using fast Fourier transformation [16].
To separate the airway and tissue mechanics, a model
containing a frequency-independent resistance (Raw)
and inertance (Iaw) in series with a constant-phase tis-
sue model [18] including tissue damping (G) and ela-
stance (H) was fitted to the Zrs spectra by minimizing
the differences between the measured and modelled
impedance values:
Zrs = Raw + jωIaw + (G-j H )/ωα
where j is the imaginary unit, is the angular frequency
(2f) and = 2/arctan(H/G). When this model is fitted to
Zrs spectra, the parameter Raw is primarily related to
the overall airway geometry, as the contribution of the
chest wall to the frequency-independent Newtonian
resistance is minor [19]. Similarly, the inertia of the gas
in the airways predominates in the parameter Iaw [19].
Measurement of pulmonary haemodynamics
The pulmonary arterial pressure (Ppa) was measured by
introducing a small catheter (polyethylene tubing, ID
0.88 mm, Portex, Hythe, GB) into the pulmonary artery
via the jugular vein beforethe animals were sacrificed.
This measurement was technically acceptable only in
subgroups of the main study groups, involving 7, 10, 4,
5, 2 and 6 rats in Groups CC, CS, VIP, ILO, SIL and
TEZ, respectively.
Measurement protocol and bronchoprovocation
challenges
Four weeks following the surgical preparation of ACS,
the rats were again anaesthetized and intubated, and the
experimental protocol was performed. EELV was first
measured while the rats were breathing spontaneously.
A femoral vein was then cannulated for drug delivery.
When stable hemodynamic and respiratory mechanical
conditions had been reached, a set of Zrs data including
4-6 6-s long recordings was recorded under the baseline
conditions. Increasing doses of iv methacholine (MCh)
were then administered at doses of 2, 4, 8, 12 and
24 μg/kg/min, and at each infusion rate 3-5 Zrs record-
ings were made during the development of steady-state
bronchoconstriction (usually 3-5 min after the onset of
MCh). The equivalent dose causing a 50% increase in
Raw (ED50) was calculated in each rat by linear
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Figure 1 Experimental protocol. Zrs: forced oscillatory recordings of the respiratory input impedance. MCh: methacholine.
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measured as described above.
Statistical analyses
The scatters in the parameters were expressed by the SE
values. The Kolmogorov-Smirnov test was used to test
data for normality. One-way analysis of variances
(ANOVA) was performed to test significant differences
in the parameters among the groups. Two-way repeated
measures ANOVA, with variables of treatment (i.e. the
protocol groups) and MCh dose, was used to evaluate
the effects of the various types of medication on the
precapillary PHT and subsequent lung responsiveness to
the constrictor challenge. Pairwise comparisons were
performed by means of Student-Newman-Keuls multiple
comparison procedures. Pearson correlation test was
used to assess the strength of associations between vari-
ables. Statistical tests were carried out with the signifi-
cance level set at p < 0.05.
Results
There was no significant difference in body weight
among the protocol groups either at the beginning of
the study (ranging from 340 ± 9 g to 360 ± 4 g, p =
0.11) or at the time of the experiments 4 weeks later
(ranging from 413 ± 14 g to 454 ± 12 g, p = 0.1).
Figure 2 demonstrates the systolic and diastolic values
of Ppa for the various groups. Preparation of the ACS
led to a significant increase in systolic Ppa (p = 0.036).
This PHT was significantly inhibited only by iloprost
(p = 0.035); none of the other treatments affected the
alteration in Ppa. No change in the diastolic Ppa was
detected (p = 0.15).
The baseline in the EELV and the forced oscillatory
parameters in the different groups are displayed in
Figure 3. ACS preparation ands u b s e q u e n tt r e a t m e n t s
did not affect the basal lung volume (p = 0.22), the
basal Raw (p = 0.28) or the respiratory tissue parameters
(p = 0.45).
F i g u r e4d e p i c t st h ea i r w a yr e s p o n s e st oM C hc h a l -
lenges in the groups. MCh induced a dose-dependent
bronchoconstriction of various magnitude in all groups.
ACS preparation led to the development of BHR, as illu-
strated by the significant upward shift in the dose
response-curve. Each of the drug treatments exerted a
protective effect against this hyperresponsiveness to
MCh. The MCh-induced changes in G and H were far
more moderate and did not exhibit a statistically signifi-
cant difference among the groups (p = 0.45, and p =
0.26 for G and H, respectively; Table 1).
To illustrate the effects of the various treatments on
the airway responses to MCh, the ED50 values are com-
pared in Figure 5. The BHR induced by generating a
precapillary PHT by ACS was manifested in a significant
decrease in ED50 in Group CS relative to that in Group
CC (p = 0.008). All of the treatments exerted a signifi-
cant protective potential, leading in Groups VIP and
TEZ an airway responsiveness similar to that observed
in the sham operated rats (Group CC). This parameter
revealed even overprotection of the airway responsive-
ness to MCh in Group ILO and Group SIL.
The relationships between the systolic Ppa and ED50
is depicted in Figure 6. These parameters relating to
the pulmonary haemodynamics and lung responsive-
ness exhibited a statistically significant correlation for
the entire study population (R = -0.59, p = 0.016) and
were variable for the individual study groups with clo-
sest correlation being observed in Group CS (R = -0.6)
and the weakest in rats with no intervention (Group C,
R = 0.1).
Discussion
Various treatment strategies applied against PHT act on
the imbalance between the vasoactive constrictor-prolif-
erative and vasorelaxing-antiproliferative mediators. In
the present study, we investigated whether these treat-
ments provide protection against the enhanced airway
responsiveness observed in the presence of precapillary
PHT. The results obtained in this well-validated animal
model of BHR originating from precapillary PHT
induced by ACS preparation demonstrate that all the
treatment modes studied, including the action on the
VIP, PC, NO and ET-1 pathways, exhibited a beneficial
profile in preventing the development of BHR. Pooling
of all the data points obtained from the groups revealed
that the systolic Ppa level and the magnitude of the lung
responsiveness were associated.
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Figure 2 Systolic (top of the bars) and diastolic (bottom of the
bars) pulmonary arterial pressures in the rats involved in the
different groups. CC: control group, CS: shunt, no treatments, VIP:
shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL:
shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan.
*: p < 0.05 vs the data obtained in the rats with precapillary pulmonary
hypertension with no drug treatment (Group CS).
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led to precapillary PHT, which was associated with
enhanced airway responsiveness to MCh. This experi-
mental model has been extensively validated previously
both by ourselves and by other research groups, and has
been proved to provide an increased pulmonary blood
flow leading to PHT [11-13,20]. Precise measurement of
the pulmonary haemodynamics in rats was complicated
by the small size of the animal and the lack of catheter-
tip balloon, which normally helps to introduce to the pul-
monary artery. Due to this technical difficulty, technically
acceptable Ppa recordings were possible only in about
two-third of the rats. According to literature [11,13,20],
we also noted an elevated systolic Ppa in the rats in
Group CS, confirming the validity of the experimental
model for investigation of the pulmonary consequences
of chronic precapillary PHT. It is noteworthy, however,
that the model applied here mimics clinical conditions
encountered in patients with left-to-right shunts and
increased pulmonary blood flow, and the results may not
be extrapolated to other forms of PHT. The altered
mechanical interdependence between the pulmonary vas-
culature and the respiratory tract is responsible for the
BHR in this experimental model, thus the effects of the
applied treatment strategies in the present study are valid
for this pulmonary haemodynamical abnormality.
In agreement with previous data [11], we did not
observe statistically significant changes in the baseline
values of the respiratory mechanical parameters follow-
ing sustained precapillary PHT. However, normalization
of the Raw to the lung volume revealed a statistically
significant increase in this specific Raw (p < 0.006),
which is in harmony with the earlier results that ACS
causes a detectable elevation only in the corrected
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Figure 3 The baseline end-expiratory lung volume (EELV), airway resistance (Raw), respiratory tissue damping (G) and elastance (H)
data obtained in the different groups. CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with
iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt, treatment with tezosentan.
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Page 5 of 8baseline Raw. Accordingly, it can be anticipated that the
experimental model applied here reflects the major fea-
tures of the respiratory mechanical changes encountered
under baseline conditions in patients with chronic pre-
capillary PHT.
The three major mechanisms involved in the develop-
ment of PHT are the PC, the ET and NO pathways. The
pathological changes in these pathways are manifested by
an imbalance of the mediators with vasodilation or vaso-
constriction potential. These pathways have also been
implicated in the regulation of the airway smooth muscle
tone [8,10,21,22]. Thus, we restored an optimum balance
between the constrictor/dilator mediators through selec-
tive targeting of these mechanisms to characterize whether
these treatment strategies affect lung responsiveness.
Iloprost is a PC analogue and a potent pulmonary vaso-
dilator that exerts its effect through the activation of cyclic
adenosine monophosphate (cAMP) [2]. Since the molecule
has a short half-life (approximately 20 min), we followed
the common strategy of delivering it via a continuous infu-
sion. In agreement with previous findings, this treatment
strategy effectively inhibited the PHT [23,24]. Over and
above this well-established beneficial pulmonary vascular
effect, our study is the first to demonstrate that this phar-
macotherapeutic management is associated with complete
prevention of the development of BHR.
Another essential pathway involved in the pathogenesis
of PHT is related to a dysfunction in the key pulmonary
vasodilator NO [25]. Enhancement of the NO-mediated
effects by phosphodiesterase 5 inhibitors such as sildena-
fil has therefore been proposed as an effective mode of
treatment against PHT [9,26]. NO is known to exert a
potent bronchodilation effect [27], and its overexpression
leads to a direct relaxing effect on the airway smooth
muscle. Since excessive NO in the lungs has been shown
to inhibit MCh-induced bronchoconstriction [28], this
mechanism is probably involved in the complete preven-
tion of BHR in Group SIL in the present study.
The rationale of testing the ability of tezosentan, a dual
ET-1 receptor antagonist, to prevent BHR emerged from
the crucial involvement of ET-1 in the pathogenesis of
PHT [25]. ET-1 exerts its regulatory effect on the pul-
monary vascular and bronchial tone via two receptor
subtypes (ETA and ETB). The roles of these receptor sub-
types on the pulmonary vascular and bronchial tone are
dissociated, with ETA stimulation leading to vasocon-
striction and bronchodilation [10,29], while activation of
ETB receptors results in the liberation of vasodilator
mediators with a concomitant bronchodilation potential
[10,30]. The opposing effects of ETA and ETB following
dual receptor blockade may therefore have resulted in
the lack of significant change in the Ppa in the present
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Figure 4 Methacholine-induced changes in airway resistance
(Raw) in the different groups. CC: control group, CS: shunt, no
treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment
with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt,
treatment with tezosentan. *: p < 0.05 vs the value obtained under
baseline conditions (BL) within a group; #: p < 0.05 vs. the data
obtained in the rats with precapillary pulmonary hypertension
without drug treatment (Group CS).
Table 1 Respiratory tissue parameters under baseline conditions, during MCh infusion at a dose of 24 μg/kg/min, and
their percentage changes in the different groups
G (cmH2O/l) Change in G H (cmH2O/l) Change in H
Baseline MCh 24 μg/kg/min % Baseline MCh 24 μg/kg/min %
CC 866 ± 49 1150 ± 76* 33 ± 5 2927 ± 299 3767 ± 334* 31 ± 4
CS 736 ± 42 968 ± 78* 31 ± 5 2936 ± 167 3329 ± 195* 15 ± 6
VIP 735 ± 33 991 ± 49* 37 ± 10 2589 ± 258 3139 ± 231* 24 ± 5
ILO 802 ± 84 930 ± 65* 21 ± 9 2972 ± 397 3061 ± 147 10 ± 10
SIL 964 ± 45 1159 ± 50* 21 ± 6 3240 ± 281 3741 ± 278* 16 ± 3
TEZ 727 ± 34 911 ± 58* 25 ± 3 2370 ± 156 3001 ± 232* 26 ± 2
CC: control group, CS: shunt, no treatments, VIP: shunt, treatment with VIP, ILO: shunt, treatment with iloprost, SIL: shunt, treatment with sildenafil, TEZ: shunt,
treatment with tezosentan.
*: p < 0.05 vs. the value obtained under baseline conditions within a group.
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relax the airway smooth muscle are reflected in the
potential of tezosentan to prevent BHR effectively. This
raises the unsolved controversy of the use of specific ETA
or dual blockers: clinical studies have so far failed to
reveal significant differences between selective ETA and
dual receptor blockade [31]. However, our data suggest
that the detrimental effects of precapillary PHT can be
effectively prevented by dual ET-1 receptor blockade.
VIP plays a major role in regulating the smooth mus-
cle tone around both the pulmonary vasculature and the
bronchi via the non-adrenergic non-cholinergic nervous
system [32-34]. Since VIP exerts its relaxation potential
on the smooth muscle by opening Ca
2+-activated K
+
channels through a cAMP-dependent mechanism
[35,36] and by inducing NO release from VIP/NO-con-
taining nerve fibers and the endothelium [32,37], its
inhalation has recently been advocated in the treatment
of PHT [38,39]. Although previous studies have sug-
gested the efficacy of this peptide in inducing transient
pulmonary vasodilation in another model of PHT [39],
our findings indicate that the chronic continuous intra-
peritoneal administration of VIP did not provide a
decrease in Ppa in the presence of precapillary PHT.
However, BHR was eliminated by VIP treatment, which
is in accord with previous results demonstrating its
bronchodilation properties [10,40].
Summary and conclusions
This comparison of treatment strategies aimed at reestab-
lishment of the balance between the various smooth mus-
cle constrictor and relaxation mediators revealed similar
abilities of the agonists acting on the PC, NO, ET-1 and
VIP pathways to protect the development of airway hyper-
reactivity subsequent to precapillary PHT. The pathophy-
siological mechanisms responsible for the fairly uniform
bronchial effects of the various treatments may be inferred
from the significant correlation between the lung respon-
siveness and the level of systolic PHT (Figure 6). This
close association suggests that independently of the phar-
macotherapeutical approach to influence the pulmonary
vasculature, it is the level of Ppa which determines the
lung responsiveness through the existence of a close
mechanical interdependence between the pulmonary
vasculature and the airway tree.
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